Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.55 |
| ▸ | MME | P08473 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12126314 | 0.94 | ACE (0.60) | ACEMMEALDH1A1HPGDMAPK1 | |
| SCHEMBL22199401 | 0.88 | CTSS (0.50) | ACEMMEALDH1A1HPGDMAPK1 | |
| SCHEMBL24764551 | 0.86 | ACE (0.56) | ACEMMEALDH1A1HPGDMAPK1 | |
| SCHEMBL24764552 | 0.85 | ACE (0.51) | ACEMMEALDH1A1HPGDMAPK1 | |
| SCHEMBL25148526 | 0.84 | CTSS (0.53) | ACEMMEALDH1A1HPGDMAPK1 | |
| SCHEMBL22695725 | 0.84 | CTSS (0.54) | ACEMMEALDH1A1HPGDMAPK1 | |
| SCHEMBL16656682 | 0.84 | CTSS (0.54) | ACEMMEALDH1A1HPGDMAPK1 | |
| SCHEMBL30881100 | 0.83 | CTSS (0.52) | ACEMMEALDH1A1HSD17B10CTSS | |
| SCHEMBL9388996 | 0.82 | CTSS (0.49) | ACEMMEALDH1A1HPGDMAPK1 | |
| SCHEMBL9388987 | 0.82 | CTSS (0.49) | ACEMMEALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021055690-A1 | PEPTIDE-CONJUGATED PRODRUGS | BRANDEIS UNIVERSITY (US) | 2021-03-25 | — | — | WO | disclosed |
| US-8993536-B2 | Low-molecular polysulfated hyaluronic acid derivative and medicine containing same | OTSUKA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-20110281819-A1 | LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281819-A1 | LOW-MOLECULAR POLYSULFATED HYALURONIC ACID DERIVATIVE AND MEDICINE CONTAINING SAME | HRH1, HRH2, HRH3 | ACE 2807/4885MME 1361/4885ALDH1A1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.